Thomas Gauler

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 392 citations

Medicine, Oncology, Chemotherapy +12

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

Wilfried Eberhardt, Christoph Pöttgen, Thomas Gauler et al. · Journal of Clinical Oncology · 2015 · 365 citations

Medicine, Oncology, Surgery +16

Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Robert J. Motzer, Bernard Escudier, Saby George et al. · Cancer · 2020 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II

S. Krege, Rainer Souchon, Peter Albers et al. · European Urology · 2008 · 252 citations

Medicine, Cancer Biology, Oncology +17